


Epidemiology: the big picture



Madhukar Pai, MD, PhD

Associate Professor

McGill University

madhukar.pai@mcgill.ca



McGill

Objective of the introductory lectures

- To completely put you off epidemiology
- To encourage you to seriously consider switching to another program (it is not too late!)

Why epidemiology?

- We are engaged in healthcare and health research
- To effectively practice medicine and public health, we need evidence/knowledge on 3 fundamental types of professional knowing “gnosis”:

Dia-gnosis

Etio-gnosis

Pro-gnosis

For individual
(Clinical Medicine)

Dia-gnosis

Etio-gnosis

Pro-gnosis

For community
(Public and
community
health)

Are these legitimate concerns for clinical medicine?

- Do anti-depressants reduce the risk of suicides in people with depression?
- Will daily low dose aspirin reduce the risk of acute myocardial infarction?
- Is ultrasonography accurate in detecting acute appendicitis?

Are these legitimate concerns for public health?


- Will screening with CT scans reduce risk of lung cancer deaths among smokers?
- Does passive smoking increase the risk of spontaneous abortions?
- Are probiotics effective in reducing risk of antibiotic-related diarrhea?
- Does mobile phone use increase the risk of brain cancer?

If yes, how do we answer such questions?

- Q: What is the strategy for answering salient questions for medical and public health practice?
- A: Epidemiologic research
- Without epidemiology, we would be hopelessly lost
- Even with epidemiology, we seem hopelessly lost!!

Of the 3 types of knowing (“gnosis”) etio-
gnosis (causality) is the central concern of
epidemiology

- Most fundamental application of epidemiology: to identify etiologic (causal) associations between exposure(s) and outcome(s)



Causal claims and associations are frequent in the literature and often picked up by the media

CNN.com /health POWERED BY Google

HOME WORLD U.S. POLITICS ENTERTAINMENT **HEALTH** TECH TRAVEL LIVING BUSINESS SPORT

Hot Topics » Hurricanes » Iraq » Pat Tillman » Taliban » Michael Vick » Britney Spears » Nicole Richie » More Topics

HEALTHY MEN

updated 3:14 p.m. EDT, Thu July 12, 2007

Men's Health: Truth or Myth?

STORY HIGHLIGHTS

- Do you know
- Is hair loss
- Do men hav

Next Article is

Laptops and sperm count

Truth or Myth:
Laptop computers may lower sperm count.

This actually is true. A recent study indicates that men who use a laptop computer on their lap may cause their scrotal temperatures to increase significantly. Increased testicular temperature has a well-documented link to reduced sperm count. The study concluded that long-term use of a laptop by teenage boys and young men could be damaging. The study said further testing was warranted.

Source: Oxford Journal Human Reproduction



bbc.co.uk Home TV Radio Talk Where I Live A-Z Index

UK version International version About the versions

BBC NEWS [WATCH LIVE BBC News 24](#)

Last Updated: Wednesday, 1 August 2007, 11:51 GMT 12:51 UK

[E-mail this to a friend](#) [Printable version](#)

Suicide rate rises in hot weather

The damp summer may have made us all miserable, but research suggests it is hot weather that poses a far more serious problem for vulnerable people.



Sunny weather. Not good news for all

A team from London's Institute of Psychiatry found that suicide rates go up during hot weather.

Analysis of more than 50,000 suicides in England and Wales between 1993 and 2003 showed the suicide rate rose when average daily temperatures topped 18C.

The study appears in the British Journal of Psychiatry.

The researchers found that once the daily average temperature rose above 18C each further degree increase was associated with a rise in suicides of almost 4%.

The rate in the rise of violent suicides was even higher, at 5% per degree rise in temperature.

RELATED BBC SITES
SPORT

A few cups of coffee may lower colon cancer risk

Posted: 01 August 2007 17:08 hrs

TOKYO : Drinking a few cups of coffee a day may lower the risk of advanced colon cancer, at least for women, Japanese researchers said Wednesday.

The study, supported by Japan's health ministry, showed women who drink more than three cups of coffee a day were 56 percent less likely to develop advanced colon cancer than those who drink no coffee at all.

"Drinking coffee sustains the secretion of bile acid and keeps down cholesterol levels, the mechanisms thought to prevent colon cancer," the report said.

But unfortunately the effect was not seen in men, the medical research team said.

Many men smoke and drink alcohol more than women, and those habits probably offset the effect of coffee, the study said.

The research team tracked down about 96,000 people in Japan aged from 40 to 69 between the early 1990s and 2002, of whom 726 men and 437 women later suffered colon cancer.



Causal claims are often inconsistent and contradictory!

CancerConsultants.com

oncology resource center

Critical Choices for Improving Outcomes in Renal Cell Carcinoma

Start CME

MedCases

Patient Home

Professional Home

Newsletters

Feedback Survey

Search:

Medline

CancerConsultants.com

Both

Search

Main Menu

Home

Conference Coverage

Current Topics in Oncology

Cancer News

Disease Centers

Physician Resources

About Us

Quick Links

Information by Disease

All

Cancer News

Select Cancer Type

Conference Coverage

Select Conference

Brand Your Oncology Program Online

Cancer News: Rectal Cancer: Article

Printable Version

Rectal Cancer News

Coffee Does Not Decrease Risk of Colorectal Cancer

Researchers from the Harvard School of Public Health have reported that, contrary to the results of several previous studies, coffee consumption does not appear to reduce the risk of colorectal cancer. The details of this study were reported in the April 1, 2009 issue of the *International Journal of Cancer*.[\[1\]](#)

Habitual coffee drinking has been associated with a reduced risk of mortality and chronic diseases, including cancer. Current evidence suggests that coffee consumption is associated with a reduced risk of liver, kidney, and to a lesser extent, premenopausal breast cancer and colorectal cancer; coffee consumption has no association with prostate, pancreas, and ovarian cancers.

Some studies have indicated that coffee may have a protective effect against colon cancer; however, researchers continue to evaluate this link in an effort to establish more direct evidence. In order to examine the relationship between coffee consumption and colorectal cancer, researchers from Harvard conducted a review of 12 studies that included 646,848 participants and 5,403 cases of colorectal cancer.

They evaluated high versus low coffee consumption and found no significant effect of coffee consumption on colorectal cancer risk. The review included four studies in the United States, five in Europe, and three in Japan. The data from each country was very similar. There were no significant differences by gender or site of cancer; however, there was a slight inverse relationship between coffee consumption and colon cancer for women, which was even more pronounced among Japanese women (21% for total study, 38% for Japanese women).

The researchers observed that inverse associations between coffee consumption and colorectal cancer "were slightly stronger in studies that controlled for smoking and alcohol and in studies with shorter follow-up times."

They concluded that coffee is "unlikely to have a strong protective effect on colorectal cancer risk"; however, they also note that it does not appear to increase the risk of colorectal cancer either.

HRT 'doubles breast cancer risk'

Taking certain types of hormone replacement therapy (HRT) can double the risk of developing breast cancer, says a study of more than a million women.



Breast cancer could be more deadly after HRT

The largest ever study into the link between HRT and breast cancer was conducted by scientists at Cancer Research UK's Epidemiology Unit in Oxford.

The research suggests the single pill moderately increases the risk of breast cancer, but the combined pill doubles the risk.

It estimates HRT, taken by women to relieve the unpleasant symptoms of menopause, may have been responsible for an extra 20,000 cases of the disease in Britain in the last decade.



Africa
Americas
Asia-Pacific
Europe
Middle East
South Asia
UK

Business

Health

Medical notes

Science/Nature

Technology

Entertainment

Also in the news

Video and Audio

Have Your Say

In Pictures

Country Profiles

Special Reports

RELATED BBC SITES

SPORT

Health

Diet & Nutrition

Fitness

Women's Health

Kids & Parenting

Men's Health

Sexual Health

Aging

Heart Health

Cancer

Pregnancy

Infectious

Diseases

Mental Health

More Health

News

Pet Health

Skin & Beauty

Health Library

Health Columns

BabyQuest

Video

U.S. News

Politics

World News

Combo HRT linked to lower-risk breast cancers

Tumors tend have better prognosis than after estrogen-only therapy

REUTERS

Updated: 8:42 p.m. ET June 5, 2007

The types of breast tumors that occur after [combination hormone replacement therapy](#) in women going through menopause and in post-menopausal women tend to have a better prognosis than those that occur after estrogen-only replacement therapy, Swedish researchers report.

A team at Malmo University Hospital conducted a study involving 12,583 perior post-menopausal women whose medical records were linked to national cancer registries. Of the group, 513 had a [history of breast cancer](#) prior to

Q & A library

Click on a topic to learn more:

[Breast cancer](#)

[Ovarian cancer](#)

[Colon cancer](#)

[Prostate cancer](#)

[Melanoma](#)

Related Stories

[What's this?](#)

[Is it safe to get pregnant after breast cancer?](#)

[Older women shouldn't take hormones](#)

[Group therapy doesn't extend life in cancer](#)

[Early Ovarian Surgery Linked to Dementia](#)

Health News

Drinking and Dementia: Is There a Link?

FONT SIZE

A A A

Study Shows Drinkers With Genetic Predisposition to Alzheimer's Disease at Higher Risk

 By Salynn Boyles
 WebMD Medical News

Sept. 2, 2004 -- Drinking alcohol in middle age may increase the risk of late-life dementia in people who are genetically predisposed to develop Alzheimer's disease, according to findings from a Scandinavian study.

Researchers from Stockholm's Karolinska Institute reported that infrequent drinkers have a twofold increase in the risk of dementia in old age among carriers of a gene that has been linked to Alzheimer's. Gene carriers who frequently drink had a threefold increase in risk.

But the findings also show a protective effect for infrequent drinkers who did not have the genetic risk factor. Low-risk teetotalers and frequent drinkers in the study were twice as likely to experience mild cognitive declines later in life as infrequent drinkers.

The findings are reported in the Sept. 4 issue of the *BMJ* (formerly the *British Medical Journal*).

 ADVERTISEMENT
life'sDHA
 Sample Daily Menu

 What's your
 Daily DHA?

ADVERTISEMENT

WebMD newsletter
WebMD Daily

 Your must-read health
 news source.

BBC NEWS

 You are in: [Health](#)

Friday, 25 January, 2002, 12:13 GMT

Alcohol 'could reduce dementia risk'


[Front Page](#)
[World](#)
[UK](#)
[UK Politics](#)
[Business](#)
[Sci/Tech](#)
[Health](#)
[Background](#)
[Briefings](#)
[Medical notes](#)
[Education](#)
[Entertainment](#)
[Talking Point](#)
[In Depth](#)
[AudioVideo](#)
BBC SPORT
BBC Weather
SERVICES
[Daily E-mail](#)
[News Ticker](#)
[Mobiles/PDAs](#)
[Feedback](#)
[Help](#)
[Low Graphics](#)

Moderate alcohol consumption could be beneficial. Small amounts of alcohol could reduce the risk of dementia in older people regardless of the type of alcoholic drink consumed, research suggests.

It is known that light-to-moderate consumption lessens the risk of coronary heart disease and stroke, but Dutch scientists think it could be good for mental health.

See also:

- ▶ 17 Apr 01 | Health Alcohol 'protects old against heart failure'
- ▶ 01 Feb 01 | Health £6bn bill for alcohol abuse
- ▶ 06 Dec 00 | Health Alcohol 'improves IQ'
- ▶ 15 Apr 01 | Health Why alcohol affects women more
- ▶ 06 Jan 01 | Health Alcohol 'cuts strokes in women'
- ▶ 18 Dec 00 | Health Beer 'keeps cataracts away'
- ▶ 30 Oct 00 | Health Alcoholic liver disease linked to genes

Internet links:

- ▶ [British Heart Foundation](#)
- ▶ [The Lancet](#)
- ▶ [Alzheimer's Society](#)

From The Times

July 24, 2007

Taking statins may increase cancer risk



Nigel Hawkes, Health Editor

Lowering cholesterol with statins may slightly increase the risk of cancer, a study suggests.

It is not clear whether the cancer cases are caused by the drugs, or are a consequence of the low levels of "bad" LDL cholesterol produced by taking them.

EXPLORE HEALTH

- > OUR EXPERTS
- > FEATURES
- > HEALTHY EATING
- > COMPLEMENTARY MEDICINE
- > CHILD HEALTH

ASK THE TIMES DOCTOR



Heart problems?

Medscape
Medical News

Statins Lower Cancer Risk

June 5, 2003 (Chicago) — Cholesterol-lowering statin drugs are associated with a statistically significant 20% reduction in cancer risk, a case-control shows. But researchers at the presentation here at the 39th annual meeting of the American Society of Clinical Oncology were quick to add that it's too soon to recommend that patients take the agents for cancer prevention.

"Given the high number of people already on statins, the impact on public health could be quite considerable," said chief investigator Matthijs Graaf, PharmD, from the University of Amsterdam. "But since this is a case-control study, we need confirmation in a prospective randomized trial before we can suggest people take these agents to lower cancer risk."

William Gradishar, MD, from Northwestern University Feinberg School of Medicine in Chicago, Illinois, and moderator of a press conference at which the findings were discussed, agreed.

"This is provocative data," he said. "But the problem with interpreting it is that it's a population-based study. To make a blanket statement that statins should be used for cancer prevention would be premature."

Information from Industry

Assess clinically focused product information on Medscape.

- [Click Here for Product Infosites -- Information from Industry.](#)

Studies clash on vitamin benefits

By Elizabeth Landau, CNN

April 19, 2010 8:56 a.m. EDT



THINKSTOCK

Doctors recommend against taking multivitamin supplements if you can get the same nutrients in foods.

STORY HIGHLIGHTS

- Vitamins and calcium show protective effects against breast cancer in a Puerto Rican study
- A large Swedish study finds that vitamins may increase risk of breast cancer
- A diet high in B-vitamins is found to lower heart risks in Japanese study

(CNN) -- To take the multivitamin or to not take the multivitamin: That is the question researchers are still trying to answer.

New research on [vitamins](#) has offered conclusions that weren't crystal clear. But researchers generally recommend getting vitamins from foods, not supplements, to boost your health.

Vitamin supplements and cancer

Gene for Depression

2003

[HOME PAGE](#) [TODAY'S PAPER](#) [VIDEO](#) [MOST POPULAR](#) [TIMES TOPICS](#)

The New York Times

Health

[WORLD](#) [U.S.](#) [N.Y. / REGION](#) [BUSINESS](#) [TECHNOLOGY](#) [SCIENCE](#) [HEALTH](#) [SPORTS](#) [OPINION](#)

[RESEARCH](#) [FITNESS & NUTRITION](#) [MONEY & POLICY](#) [VIEWS](#)

Introducing Microsoft Online Services

Choice is good.

▶ See for Yourself

Gene Is Linked to Susceptibility to Depression

By MARY DUENWALD
Published: Friday, July 18, 2003

Scientists have identified a gene that may help explain why some people become depressed in response to the stresses of life and others skate by relatively unscathed.

The gene, which comes in two forms, or alleles, can either protect people from depression or make them more vulnerable, researchers report today in the journal Science.

In the study, people who experienced job loss, death in the family, abuse or other traumas were much more likely to develop depression if they possessed two copies of the short allele. Those with two copies of the long allele (pronounced uh-LEEL) were able to withstand such events without becoming depressed.

"No matter how many stressful events they had in a five-year period, they were no more likely to become depressed than people who had

☒ SIGN IN TO RECOMMEND

[SIGN IN TO E-MAIL](#)

PRINT

REPRINTS

[SHARECLOSE](#)

LINKEDIN

DIGG

FACEBOOK

MIXX

MYSPACE

YAHOO! BUZZ

PERMALINK

2009

[HOME PAGE](#) [TODAY'S PAPER](#) [VIDEO](#) [MOST POPULAR](#) [TIMES TOPICS](#)

The New York Times | **International Herald Tribune**

GLOBAL EDITION
Science

[WORLD](#) [U.S.](#) [N.Y. / REGION](#) [BUSINESS](#) [TECHNOLOGY](#) [SCIENCE](#) [HEALTH](#) [SPORTS](#) [OPINION](#) [ARTS](#)

[ENVIRONMENT](#) [SPACE & COSMOS](#)

Adobe® Acrobat® Connect™ Pro Web Conferencing

» Click here to learn more

Report on Gene for Depression Is Now Faulted

By BENEDICT CAREY
Published: June 16, 2009

One of the most celebrated findings in modern [psychiatry](#) — that a single gene helps determine one's risk of depression in response to a divorce, a lost job or another serious reversal — has not held up to scientific scrutiny, researchers reported Tuesday.

RSS Feed

[Get Science News From The New York Times »](#)

Readers' Comments

Readers shared their thoughts on this article.
[Read All Comments \(48\) »](#)

[The original finding](#), published in 2003, created a sensation among scientists and the public because it offered the first specific, plausible explanation of why some people bounce back after a stressful life event while others plunge into lasting despair.

The new report, by several of the most prominent researchers in the field,

does not imply that interactions between genes and life experiences are trivial; they are

☒ SIGN IN TO RECOMMEND

COMMENTS (48)

[SIGN IN TO E-MAIL](#)

PRINT

REPRINTS

[SHARECLOSE](#)

LINKEDIN

DIGG

FACEBOOK

MIXX

MYSPACE

YAHOO! BUZZ

PERMALINK

Next

MOST

E-M

1.

Kill or cure?

Help to make sense of the Daily Mail's ongoing effort to classify every inanimate object into those that cause cancer and those that prevent it.

A B C D E F G H I J K L M N O P R S T U V W X Y Z

If any of these results seems incorrect, please report it using the link next to the article.

air pollution **causes** cancer

- [Pollution peril 'worse at home'](#) [Incorrect?]

alcohol both **causes** and **prevents** cancer

- [Women would cut drinking to reduce cancer risk](#) [Incorrect?]
- [Drink a day increases breast cancer risk](#) [Incorrect?]
- [Who's at risk of breast cancer?](#) [Incorrect?]
- [Binge drinking 'increases breast cancer risk'](#) [Incorrect?]
- [A drink a day increases risk of breast cancer](#) [Incorrect?]
- [Cancer alert: Don't eat, drink or tan too much](#) [Incorrect?]
- [Bowel cancer danger of just one glass of wine per day](#) [Incorrect?]
- [Shocking ignorance over cancer risks](#) [Incorrect?]
- [The cancer generation: how Britons' hedonistic lifestyles are taking a terrible toll](#) [Incorrect?]
- [Mouth cancer warning for binge drinkers](#) [Incorrect?]
- [Is anything safe to eat? Cancer report adds bacon, ham and drink to danger list](#) [Incorrect?]
- [Cancer: foods to avoid?](#) [Incorrect?]
- [Modern living to blame for cancer epidemic](#) [Incorrect?]
- [80,000 cancer cases caused by diet](#) [Incorrect?]
- [10 ways to prevent breast cancer](#) [Incorrect?]
- [Forty per cent jump in female drinking fuels rise in breast cancer](#) [Incorrect?]
- [Our lifestyles are killing us: Poor diets, drinking and lack of exercise blamed for 78,000 cancer cases a year](#) [Incorrect?]
- [Binge drinking causes mouth cancer surge](#) [Incorrect?]
- [More than a third of cancer could be prevented by healthy lifestyle, say experts](#) [Incorrect?]

Help to make sense of the Daily Mail's ongoing effort to classify every inanimate object into those that cause cancer and those that prevent it.

mobile phones both **cause** and **prevent** cancer

- [Using mobile phones for more than 10 years 'doubles risk of brain cancer'](#) [Incorrect?]
- [What a top cancer researcher told his staff: Limit your mobile phone use to avoid tumours](#) [Incorrect?]
- [Why your mobile should carry a health warning like cigarette packets because of brain cancer risk](#) [Incorrect?]
- [Mobile phones 'cancer link': Mouth tumours 50% more likely after heavy use](#) [Incorrect?]
- [Mobile phone cancer risks probed](#) [Incorrect?]
- [We can't ignore the links between mobile phones and cancer like we did with tobacco, top scientists tell U.S. Congress](#) [Incorrect?]
- [Plans for 'cancer shields' in mobile phones](#) [Incorrect?]
- [Mobiles linked to eye cancer](#) [Incorrect?]
- [Mobile phones 'could cause brain tumours in long-term users'](#) [Incorrect?]
- [Old-style mobiles linked to brain cancer](#) [Incorrect?]
- [Row over 'cover up' of mobile phone masts cancer finding](#) [Incorrect?]
- [Orange to remove mobile mast from 'tower of doom', where cancer rate has soared](#) [Incorrect?]
- [Fear over first mobile phone link to cancer](#) [Incorrect?]
- [Skin cancer cases increase by 46 per cent in just seven years](#) [Incorrect?]
- [Only ten minutes on a mobile could trigger cancer, scientists believe](#) [Incorrect?]

Today's Random Medical News

from the New England
Journal of
Panic-Inducing
Gobbledygook

JIM BORGMAN



Figure 3: New England Journal of Panic-Inducing Gobbledygook.
Source: Jim Borgman, The Cincinnati Enquirer (27 April 1997, E4).

EDITORIAL



Tuberculosis Diagnosis — Time for a Game Change

Peter M. Small, M.D., and Madhukar Pai, M.D., Ph.D.

The effective treatment of tuberculosis is a life-saving intervention. The global scale-up of tuberculosis therapy has averted 6 million deaths over the past 15 years, making it one of the greatest public health interventions of our lifetime.¹ Unfortunately, by the time most patients are treated, they have already infected many others.² This failure to interrupt transmission fuels the global epidemic so that every year there are more new cases of tuberculosis than in the previous year.¹

new automated nucleic acid–amplification test that may allow a relatively unskilled health care worker to diagnose tuberculosis and detect resistance to a key antibiotic within 90 minutes. This test and others that are likely to follow have the potential to revolutionize the diagnosis of tuberculosis. Thus, in the coming years, rapid diagnosis and targeted treatment will provide the greatest opportunity for stopping the tuberculosis epidemic.

In a large, well-conducted, multicountry study,

EDITORIALS

Promoting Healthy Skepticism in the News: Helping Journalists Get It Right

Steven Woloshin, Lisa M. Schwartz, Barnett S. Kramer

Table 1. A recent medical journal article and excerpts of subsequent media coverage

The Study Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers (1)

Phase I study of olaparib in which 60 patients were enrolled with a variety of treatment refractory solid tumors. All were given the drug at various doses (to establish dosing and safety).

Response (improvement or no progression according to radiologic or tumor markers) was only seen in 12 of the 19 patients with BRCA1 or 2 mutations and ovarian, breast or prostate cancer.

Olaparib had fewer of the adverse effects typically seen with conventional chemotherapy.

Television Covered by three national television news programs: ABC, CBS, NBC

New cancer medicine might provide new era in treatment (NBC Nightly News) (2)

... [NBC's anchor]: "Now we turn to what some are calling the most important cancer treatment breakthrough in a decade. While we caution this is a small study, the New England Journal of Medicine tonight is saying it shows so much promise this could mean a whole new direction for cancer drugs, especially for those patients vulnerable to breast, ovarian and prostate cancer.

... [NBC's chief medical correspondent]: Patricia Buckles is a 29-year veteran of the battle with breast cancer, with all the suffering that surgeries and chemotherapy can bring. Almost out of options, she joined a trial of a new class of drugs, pills called PARP inhibitors.

Ms. PATRICIA BUCKLES: I went up there with growing cancer, measurable cancer, and I'm to the point now where the CAT scans show no evidence of disease.

... [NBC's chief medical correspondent]: Julian Lewis had prostate cancer that had resisted all treatments and spread throughout his body, until he got into a PARP inhibitor trial.

Mr. JULIAN LEWIS: My PSA level, which is a marker of the tumor, went right down to a very low level and it stayed low. And my bone metastases also seemed to have almost disappeared, judged from MRI scans.

... [NBC's chief medical correspondent]: As I said, many scientists believe these drugs could treat some people who don't have the genetic mutations, especially for ovarian cancer. Those studies are under way. But whatever else happens, these drugs look like they will eventually save thousand of lives."

THE SCIENCE NEWS CYCLE

JORGE CHAM © 2009

Start Here

Your Research

Conclusion: A is correlated with B ($p=0.56$), given C, assuming D and under E conditions.



...is translated by...

UNIVERSITY PR OFFICE (YES, YOU HAVE ONE)

FOR IMMEDIATE RELEASE:
SCIENTISTS FIND
POTENTIAL LINK
BETWEEN A AND B
(UNDER CERTAIN CONDITIONS).



...which is then
picked up by...

NEWS WIRE ORGANIZATIONS

A CAUSES B, SAY
SCIENTISTS.



...who are
read by ...

THE INTERNETS

[Scientists out to kill us again.](#)

POSTED BY RANDOM DUDE

Comments (377)

OMG! i kneeeew ittll

WTH???????



...then noticed by...

We saw it on a Blog!

A causes B all the time
What will this mean for Obama?

BREAKING NEWS BREAKING NEWS BREA

CNC Cable NEWS



...and caught
on ...

4 LOCAL EYEWITLESS NEWS

WHAT YOU DON'T
KNOW ABOUT "A" ...
CAN KILL YOU!
MORE AT 11...



...eventually
making it to...

YOUR GRANDMA





CATEGORIES: [HEALTH](#)

Right out of the mouths of snakes

The magic ingredient in the \$525-a-jar cream sold at Saks and Harrods: viper venom

by Alexandra Shimo on Thursday, April 15, 2010 9:30am - 1 Comment




Getty; iStock; Photo Illustration by Adam Cholewa

The venom of the temple viper, or *Tropidolaemus wagleri*, causes a mouse to stop breathing, its muscles paralyzed. It dies within minutes, and it is this phenomenon, or at least the paralytic quality, that made scientists realize its potential as a skin cream.

Forty-five female volunteers, aged between 40 to 60, were told to use the cream twice daily for 28 days. Some were given the snake venom cream, others another anti-aging cream, and some a placebo. The product seemed to work well—using a highly sensitive camera, the scientists measured a 73 per cent improvement of forehead wrinkles. But then again, the placebo had almost the same success rate (71 per cent) as did the other anti-aging cream (73 per cent). Even in a lab report, it seems, beauty can be in the eye of the beholder.

Costing \$525, it works out to \$17.50 per millilitre. But that doesn't seem to have deterred the excitement over the cream. Described on fashion blogs and in the media as “Botox in a bottle,” a “miracle drug” or “better than Botox,” the cream produces serious results, says Daniella Durov, a sales representative at the Toronto upscale retailer Andrews, which carries the cream. **“Our clients all come back and they love it. They can't be without it, not even for a week.”**



Whats in Airborne

Airborne dietary supplement was created by a school teacher. Since then it's become one of the best-selling, best-known supplements available, containing a special blend of Zinc, Ginger, Echinacea and 13 other vitamins, minerals and herbs. The key ingredients in Airborne have been shown to support the immune system, as shown in scientific studies and medical journals.

Select a supplement below to learn more:

Vitamin A

Vitamin C

Vitamin E

Zinc

Selenium

Manganese

Magnesium

Proprietary Herbal Blend

Riboflavin

Amino Acids

Vitamin A.

Vitamin A includes several compounds known as retinoids. These retinoids support the immune system through their antioxidant properties. Oxidation damages immune cells decreasing cell-mediated immunity. Vitamin A supplementation supports the body's immune system by protecting the cell-mediated immunity. In addition, vitamin A works synergistically with other antioxidants that support the immune system such as vitamin C, E, selenium, and manganese.



L'OREAL
PARIS

REVITALIFT® DEEP-SET WRINKLE REPAIR REGIMEN

Take the 8-Week Challenge ▶



SPIRIT

HEALTH

STYLE

RELATIONSHIPS

HOME & GARDEN

FOOD

ENTERTAINMENT

MONEY

WORLD

EXCLUSIV

VIDEOS

CONTRIBUTORS

PHOTOS

AUDIO

MESSAGE BOARDS

SUBSCRIBE TO MAGAZINE

Enter Search Term Here



[Homepage](#) » [The Oprah Winfrey Show](#) » [The Secrets of Success](#)

The Secrets of Success

The Oprah Winfrey Show | September 30, 2004

◀ BACK

NEXT ▶



Share This:

0

0
tweets



f Share

tweet

Email This



2 of 10

As a teacher and a mother, Victoria found herself catching colds all the time. In her spare time, Victoria took to her kitchen to wage war on the common cold. Within six months she had created the prototype for Airborne, her all-natural cold fighter. Her friends and family started using it and Victoria says no one was getting sick. So she and her husband set up shop in their home and began to market Airborne. The accounting office was in the dining room, one of the bedrooms was the marketing office and the bathroom was shipping and receiving! The orders started pouring in and in the first year, Victoria made \$25,000—the same as her teaching salary.

Scientific evidence for popular health supplements showing tangible human health benefits when taken orally by an adult with a healthy diet



Scientific evidence for popular health supplements showing tangible human health benefits when taken orally by an adult with a healthy diet



David McCandless and Andy Perkins / May 2011
InformationIsBeautiful.net / andyperkins.org

Source: PubMed, Cochrane.org.
Large human blind placebo-controlled trials only.
Research: Miriam Quick

Two books worth reading!



Bad Science is recommended reading for this course!

Some of this is quackery, but some is just poor science and limitations of epidemiology

SPECIAL NEWS REPORT

Epidemiology Faces Its Limits

The search for subtle links between diet, lifestyle, or environmental factors and disease is an unending source of fear—but often yields little certainty

The news about health risks comes thick and fast these days, and it seems almost constitutionally contradictory. In January of last year, for instance, a Swedish study found a significant association between residential radon exposure and lung cancer. A Canadian study did not. Three months later, it was pesticide residues. The *Journal of the National Cancer Institute* published a study in April reporting—contrary to previous, less powerful studies—that the presence of DDT metabolites in the bloodstream seemed to have no effect on the risk of breast cancer. In October, it was abortions and breast cancer. Maybe yes. Maybe no. In January of this year it was electromagnetic fields (EMF) from power lines. This time a study of electric utility



Anxiety epidemic. Protesting risks that may—or may not—be real.

on the press for its reporting of epidemiology, and even on the public “for its unrealistic expectations” of what modern medical research can do for their health. But many epidemiologists interviewed by *Science* say the problem also lies with the very nature of epidemiologic studies—in particular those that try to isolate causes of noninfectious disease, known variously as “observational” or “risk-factor” or “environmental” epidemiology.

The predicament of these studies is a simple one: Over the past 50 years, epidemiologists have succeeded in identifying the more conspicuous determinants of noninfectious diseases—smoking, for instance, which can increase the risk of developing lung cancer by as much as 3000%. Now they are left to search for subtler links be-

Rothman, editor of the journal *Epidemiology*: “We’re pushing the edge of what can be done with epidemiology.”

With epidemiology stretched to its limits or beyond, says Dimitrios Trichopoulos, head of the epidemiology department at the Harvard School of Public Health, studies will inevitably generate false positive and false negative results “with disturbing frequency.” Most epidemiologists are aware of the problem, he adds, “and tend to avoid causal inferences on the basis of isolated studies or even groups of studies in the absence of compelling biomedical evidence. However, exceptions do occur, and their frequency appears to be increasing.” As Trichopoulos explains, “Objectively the problems are not more than they used to be, but the pressure is greater on the profession, and the number who practice it is greater.”

As a result, journals today are full of studies suggesting that a little risk is not nothing at all. The findings are often touted in press releases by the journals that publish them or by the researchers’ institutions, and newspapers and other media often report the claims uncritically (see box on p. 166). And



“People don’t take us seriously ... and when they do ... we may unintentionally do more harm than good.”

—Dimitrios Trichopoulos

A 1995 report in *Science* flayed epidemiology and this led to a lot of soul searching

Taubes returned in 2007, to take another swing at epidemiology!



“Much of what we’re told about diet, lifestyle and disease is based on epidemiologic studies.

What if it is just bad science?”

Why Most Published Research Findings Are False

John P. A. Ioannidis

Summary

There is increasing concern that most current published research findings are false. The probability that a research claim is true may depend on study power and bias, the number of other studies on the same question, and, importantly, the ratio of true to no relationships among the relationships probed in each scientific field. In this framework, a research finding is less likely to be true when the studies conducted in a field are smaller; when effect sizes are smaller; when there is a greater number and lesser preselection of tested relationships; where there is greater flexibility in designs, definitions, outcomes, and analytical modes; when there is greater financial and other interest and prejudice; and when more teams are involved in a scientific field in chase of statistical significance. Simulations show that for most study designs and settings, it is more likely for a research claim to be false than true. Moreover, for many current scientific fields, claimed research findings may often be simply accurate measures of the prevailing bias. In this essay, I discuss the implications of these problems for the conduct and interpretation of research.

factors that influence this problem and some corollaries thereof.


Modeling the Framework for False Positive Findings

Several methodologists have pointed out [9–11] that the high rate of nonreplication (lack of confirmation) of research discoveries is a consequence of the convenient, yet ill-founded strategy of claiming conclusive research findings solely on the basis of a single study assessed by formal statistical significance, typically for a p -value less than 0.05. Research is not most appropriately represented and summarized by p -values, but, unfortunately, there is a widespread notion that medical research articles

It can be proven that most claimed research findings are false.

should be interpreted based only on p -values. Research findings are defined here as any relationship reaching formal statistical significance, e.g., effective interventions, informative predictors, risk factors, or associations. “Negative” research is also very useful

is characteristic of the field and can vary a lot depending on whether the field targets highly likely relationships or searches for only one or a few true relationships among thousands and millions of hypotheses that may be postulated. Let us also consider, for computational simplicity, circumscribed fields where either there is only one true relationship (among many that can be hypothesized) or the power is similar to find any of the several existing true relationships. The pre-study probability of a relationship being true is $R/(R + 1)$. The probability of a study finding a true relationship reflects the power $1 - \beta$ (one minus the Type II error rate). The probability of claiming a relationship when none truly exists reflects the Type I error rate, α . Assuming that c relationships are being probed in the field, the expected values of the 2×2 table are given in Table 1. After a research finding has been claimed based on achieving formal statistical significance, the post-study probability that it is true is the positive predictive value, PPV. The PPV is also the complementary probability of what Wacholder et al. have called the false positive report probability [10]. According to the 2



THE FALSE POSITIVE RESEARCH CYCLE

(Choi, 1998)

Contradicted and Initially Stronger Effects in Highly Cited Clinical Research

John P. A. Ioannidis, MD

CLINICAL RESEARCH ON IMPORTANT questions about the efficacy of medical interventions is sometimes followed by subsequent studies that either reach opposite conclusions or suggest that the original claims were too strong. Such disagreements may upset clinical practice and acquire publicity in both scientific circles and in the lay press. Several empirical investigations have tried to address whether specific types of studies are more likely to be contradicted and to explain observed controversies. For example, evidence exists that small studies may sometimes be refuted by larger ones.^{1,2}

Similarly, there is some evidence on disagreements between epidemiological studies and randomized trials.³⁻⁵ Prior investigations have focused on a variety of studies without any particular attention to their relative importance and scientific impact. Yet, most research publications have little impact while a small minority receives

Context Controversy and uncertainty ensue when the results of clinical research on the effectiveness of interventions are subsequently contradicted. Controversies are most prominent when high-impact research is involved.

Objectives To understand how frequently highly cited studies are contradicted or find effects that are stronger than in other similar studies and to discern whether specific characteristics are associated with such refutation over time.

Design All original clinical research studies published in 3 major general clinical journals or high-impact-factor specialty journals in 1990-2003 and cited more than 1000 times in the literature were examined.

Main Outcome Measure The results of highly cited articles were compared against subsequent studies of comparable or larger sample size and similar or better controlled designs. The same analysis was also performed comparatively for matched studies that were not so highly cited.

Results Of 49 highly cited original clinical research studies, 45 claimed that the intervention was effective. Of these, 7 (16%) were contradicted by subsequent studies, 7 others (16%) had found effects that were stronger than those of subsequent studies, 20 (44%) were replicated, and 11 (24%) remained largely unchallenged. Five of 6 highly-cited nonrandomized studies had been contradicted or had found stronger effects vs 9 of 39 randomized controlled trials ($P = .008$). Among randomized trials, studies with contradicted or stronger effects were smaller ($P = .009$) than replicated or unchallenged studies although there was no statistically significant difference in their early or overall citation impact. Matched control studies did not have a significantly different share of refuted results than highly cited studies, but they included more studies with "negative" results.

Conclusions Contradiction and initially stronger effects are not unusual in highly cited research of clinical interventions and their outcomes. The extent to which high citations may provoke contradictions and vice versa needs more study. Controversies are most common with highly cited nonrandomized studies, but even the most highly cited randomized trials may be challenged and refuted over time, especially small ones.

JAMA. 2005;294:218-228

www.jama.com

Persistence of Contradicted Claims in the Literature

Athina Tatsioni, MD

Nikolaos G. Bonitsis, MD

John P. A. Ioannidis, MD

SOME RESEARCH FINDINGS THAT have received wide attention in the scientific community, as proven by the high citation counts of the respective articles, are eventually contradicted by subsequent evidence.¹ A number of such high-profile contradictions pertain to differences between nonrandomized and randomized studies. For example, the effect of vitamin E on cardiovascular disease prevention has been in the center of a major debate in clinical research over the last 2 decades. Vitamin E is known to have antioxidant activity, and a long list of citations in the preclinical literature on antioxidants²⁻⁴ suggested that these agents may be beneficial for cancer and cardiovascular disease. Two highly cited publications suggested in the 1990s that vitamin E could decrease cardiovascular disease risk by almost half in men and in women.^{5,6} However, subsequent randomized trials showed no benefit or even suggested increased harm.^{7,8} Several other highly prominent contradictions have also been recorded pertaining to the effects of other dietary components and hormones.⁹⁻¹⁵ The prominent refutation of the epidemiological studies has spurred considerable controversy for observational epidemiology in general.¹⁶⁻²¹

Such debate offers opportunities to

Context Some research findings based on observational epidemiology are contradicted by randomized trials, but may nevertheless still be supported in some scientific circles.

Objectives To evaluate the change over time in the content of citations for 2 highly cited epidemiological studies that proposed major cardiovascular benefits associated with vitamin E in 1993; and to understand how these benefits continued being defended in the literature, despite strong contradicting evidence from large randomized clinical trials (RCTs). To examine the generalizability of these findings, we also examined the extent of persistence of supporting citations for the highly cited and contradicted protective effects of beta-carotene on cancer and of estrogen on Alzheimer disease.

Data Sources For vitamin E, we sampled articles published in 1997, 2001, and 2005 (before, early, and late after publication of refuting evidence) that referenced the highly cited epidemiological studies and separately sampled articles published in 2005 and referencing the major contradicting RCT (HOPE trial). We also sampled articles published in 2006 that referenced highly cited articles proposing benefits associated with beta-carotene for cancer (published in 1981 and contradicted long ago by RCTs in 1994-1996) and estrogen for Alzheimer disease (published in 1996 and contradicted recently by RCTs in 2004).

Data Extraction The stance of the citing articles was rated as favorable, equivocal, and unfavorable to the intervention. We also recorded the range of counterarguments raised to defend effectiveness against contradicting evidence.

Results For the 2 vitamin E epidemiological studies, even in 2005, 50% of citing articles remained favorable. A favorable stance was independently less likely in more recent articles, specifically in articles that also cited the HOPE trial (odds ratio for 2001, 0.05 [95% confidence interval, 0.01-0.19; $P < .001$] and the odds ratio for 2005, 0.06 [95% confidence interval, 0.02-0.24; $P < .001$], as compared with 1997), and in general/internal medicine vs specialty journals. Among articles citing the HOPE trial in 2005, 41.4% were unfavorable. In 2006, 62.5% of articles referencing the highly cited article that had proposed beta-carotene and 61.7% of those referencing the highly cited article on estrogen effectiveness were still favorable; 100% and 96%, respectively, of the citations appeared in specialty journals; and citations were significantly less favorable ($P = .001$ and $P = .009$, respectively) when the major contradicting trials were also mentioned. Counterarguments defending vitamin E or estrogen included diverse selection and information biases and genuine differences across studies in participants, interventions, counterinterventions, and outcomes. Favorable citations to beta-carotene, long after evidence contradicted its effectiveness, did not consider the contradicting evidence.

Conclusion Claims from highly cited observational studies persist and continue to be supported in the medical literature despite strong contradictory evidence from randomized trials.

JAMA. 2007;298(21):2517-2526

www.jama.com

Why Most Discovered True Associations Are Inflated

John P. A. Ioannidis

Abstract: Newly discovered true (non-null) associations often have inflated effects compared with the true effect sizes. I discuss here the main reasons for this inflation. First, theoretical considerations prove that when true discovery is claimed based on crossing a threshold of statistical significance and the discovery study is underpowered, the observed effects are expected to be inflated. This has been demonstrated in various fields ranging from early stopped clinical trials to genome-wide associations. Second, flexible analyses coupled with selective reporting may inflate the published discovered effects. The vibration ratio (the ratio of the largest vs. smallest effect on the same association approached with different analytic choices) can be very large. Third, effects may be inflated at the stage of interpretation due to diverse conflicts of interest. Discovered effects are not always inflated, and under some circumstances may be deflated—for example, in the setting of late discovery of associations in sequentially accumulated overpowered evidence, in some types of misclassification from measurement error, and in conflicts causing reverse biases. Finally, I discuss potential approaches to this problem. These include being cautious about newly discovered effect sizes, considering some rational down-adjustment, using analytical methods that correct for the anticipated inflation, ignoring the magnitude of the effect (if not necessary), conducting large studies in the discovery phase, using strict protocols for analyses, pursuing complete and transparent reporting of all results, placing emphasis on replication, and being fair with interpretation of results.

(Epidemiology 2008;19: 640–648)

prognostic studies, and so forth. I start here with the assumption that a research finding is indeed true (non-null), ie, it reflects a genuine association that is not entirely due to chance or biases (confounding, misclassification, selection biases, selective reporting, or other). The question is: do the effect sizes for such associations, at the time they are first discovered and published in the scientific literature, accurately reflect the true effect sizes?

The article has the following sections: a brief literature review on inflated early-effect sizes based on theoretical and empirical considerations; a description of the major reasons why early discovered effects are inflated and the major countering forces that may occasionally lead to deflated effects (underestimates); and suggestions on how to deal with these problems.

Evidence About Inflated Early-Effect Sizes

Table 1 cites articles suggesting that early studies give (on average) inflated estimates of effect.^{2–34} I list here only selected evaluations that cover either many different articles/effects or a whole research domain or method. This list is nowhere close to exhaustive. For some topics, such as the inflation of regression coefficients for variables selected through stepwise statistical-significance-based processes, the literature is

SPECIAL ARTICLE

Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy

Erick H. Turner, M.D., Annette M. Matthews, M.D., Eftihia Linardatos, B.S.,
Robert A. Tell, L.C.S.W., and Robert Rosenthal, Ph.D.

ABSTRACT

BACKGROUND

Evidence-based medicine is valuable to the extent that the evidence base is complete and unbiased. Selective publication of clinical trials — and the outcomes within those trials — can lead to unrealistic estimates of drug effectiveness and alter the apparent risk–benefit ratio.

METHODS

We obtained reviews from the Food and Drug Administration (FDA) for studies of 12 antidepressant agents involving 12,564 patients. We conducted a systematic literature search to identify matching publications. For trials that were reported in the literature, we compared the published outcomes with the FDA outcomes. We also compared the effect size derived from the published reports with the effect size derived from the entire FDA data set.

RESULTS

Among 74 FDA-registered studies, 31%, accounting for 3449 study participants, were not published. Whether and how the studies were published were associated with the study outcome. A total of 37 studies viewed by the FDA as having positive results were published; 1 study viewed as positive was not published. Studies viewed by the FDA as having negative or questionable results were, with 3 exceptions, either not published (22 studies) or published in a way that, in our opinion, conveyed a positive outcome (11 studies). According to the published literature, it appeared that 94% of the trials conducted were positive. By contrast, the FDA analysis showed that 51% were positive. Separate meta-analyses of the FDA and journal data sets showed that the increase in effect size ranged from 11 to 69% for individual drugs and was 32% overall.

While almost all trials with “positive” results on antidepressants had been published, trials with “negative” results submitted to the US Food and Drug Administration, with few exceptions, remained either unpublished or were published with the results presented so that they would appear “positive”

Non-replicated studies and publication bias

Human
Heredity

Hum Hered 2007;64:203–213
DOI: [10.1159/000103512](https://doi.org/10.1159/000103512)

Received
Accepted
Published

Non-Replication and Inconsistency in the Genome-Wide Association Setting

John P.A. Ioannidis

Clinical and Molecular Epidemiology Unit and Evidence-Based Medicine and Clinical Trials Unit,
Department of Hygiene and Epidemiology, University of Ioannina School of Medicine,
Biomedical Research Institute-Foundation for Research and Technology-Hellas, Ioannina, Greece;
Department of Medicine, Tufts University School of Medicine, Boston, Mass., USA



available at www.sciencedirect.com

ScienceDirect

journal homepage: www.ejconline.com



Almost all articles on cancer prognostic markers report statistically significant results

Panayiotis A. Kyzas^a, Despina Denaxa-Kyza^a, John P.A. Ioannidis^{a,b,c,*}

BRAVE THINKERS: **THE SCIENTIST**

MUCH OF WHAT MEDICAL RESEARCHERS conclude in their studies is misleading, exaggerated, or flat-out wrong. So why are doctors—to a striking extent—still drawing upon misinformation in their everyday practice? Dr. John Ioannidis has spent his career challenging his peers by exposing their bad science.

LIES, DAMNED LIES, AND MEDICAL SCIENCE

By DAVID H. FREEDMAN



SCIENTIFIC AMERICAN™

Winner of the 2011
National Magazine Award
for General Excellence

Search ScientificAmerican.com

News & Features • Blogs • Multimedia • Education • Citizen Science • Topics

Home » Scientific American Magazine » June 2011

Forum | Health

Tweet 3 Like 652



An Epidemic of False Claims

Competition and conflicts of interest distort too many medical findings

By John P. A. Ioannidis | May 31, 2011 | 20

Share Email Print

1 2 Next >

False positives and exaggerated results in peer-reviewed scientific studies have reached epidemic proportions in recent years. The problem is rampant in economics, the social sciences and even the natural sciences, but it is particularly egregious in biomedicine. Many studies that claim some drug or treatment is beneficial have turned out not to be true. We need only look to conflicting findings about beta-carotene, vitamin E, hormone treatments, Vioxx and Avandia. Even when effects are genuine, their true magnitude is often smaller than originally claimed.



Image: Illustration by Ben Gibson

State-of-the-art: epidemiology is a mess!

- Too many causal claims; optimism bias is pervasive
- Inconsistency in study findings and too many apparent contradictions
- Causal inferences made on the basis of isolated studies
- Many studies biased or inconclusive or false
- Most discovered true associations are inflated
- Fear and panic inducing rather than helpful; media-induced hype
- Cannot detect small effects; big effects are not to be found anymore
- Lack of consistency in concepts and terminology
- Accused of being too “fuzzy” and not rigorous

Given this mess, here are some key questions:

- Where is the guarantee that causal claims are true?
- Can epidemiological studies be wrong?
- Can they make misleading conclusions?
- How can we know when a study result is incorrect?
- Is common sense adequate to judge and interpret epidemiologic literature?

Causality: is it intuitive?

- Most of us intuitively understand causality, even if we have never formally studied it!
- Even as children, we grow up making associations and causal connections
- However, is epidemiology merely applying common sense?

Are senior surgeons incompetent?



Does anti-snake venom help or kill?

Clinical predictors of in-hospital mortality in patients with snake bite: a retrospective study from a rural hospital in central India

Shriprakash Kalantri^{1,2}, Amandeep Singh¹, Rajnish Joshi^{1,2}, Samuel Malamba², Christine Ho², Joseph Ezoua² and Maureen Morgan²

¹ Department of Medicine, Mahatma Gandhi Institute of Medical Sciences, Sevagram, India

² Division of Epidemiology, University of California at Berkeley, Berkeley CA, USA

Summary

OBJECTIVE To determine the association between selected admission risk factors and in-hospital mortality in patients admitted with venomous snake bite to a rural tertiary care hospital in central India. **METHODS** Retrospective cohort study of patients aged 12 years or older admitted to a rural hospital in central India between January 2000 and December 2003 with venomous snake bites. The primary endpoint was in-hospital mortality. We used Cox proportional-hazards regression analysis to evaluate the association between risk factors (home-to-hospital distance, bite-to-hospital time, vomiting, neurotoxicity, urine albumin, serum creatinine concentration and whole-blood clotting time) and in-hospital mortality.

RESULTS Two hundred and seventy-seven patients [mean age 32 (SD 12) years; 188 men (68%)] were admitted with venomous snake bite, 29 patients (11%) died. The probability of survival at day 7 was 83%. Vomiting [hazard ratio 6.51 (95% CI 1.94–21.77), $P \leq 0.002$], neurotoxicity [hazard ratio 3.15 (95% CI 1.45–6.83), $P = 0.004$] and admission serum creatinine concentration [hazard ratio 1.35 (95% CI 1.17–1.56), $P \leq 0.001$] were associated with higher risk of death in the adjusted analysis.

CONCLUSIONS In our rural hospital setting, the overall mortality rate was 11 per 100 cases of snake bite. Vomiting, neurotoxicity and serum creatinine are significant predictors of mortality among inpatients with snake bite. These predictors can help clinicians assess prognosis of their patients more accurately and parsimoniously and also serve as useful signposts for clinical decision-making.


Does pet ownership reduce risk of cardiovascular disease?



Does HRT lower CHD risk?

- HRT was shown to reduce coronary heart disease (CHD) in women in several observational studies
- Subsequently, RCTs showed that HRT might actually increase the risk of heart disease in women
- What can possibly explain the discrepancy between observational and interventional studies?
 - Women on HRT in observational studies were more health conscious, thinner, and more physically active, and they had a higher socioeconomic status and better access to health care than women who are not on HRT
 - Self-selection of women into the HRT user group could have generated uncontrollable confounding and lead to "healthy-user bias" in observational studies.
 - Also, individuals who adhere to medication have been found to be healthier than those who do not, which could produce a "compliance bias"
 - Furthermore, there is the issue of "prescriber effect" and "eager patient effect"
- Full story in Gary Taubes' NYT article!
- Also see a B-File on the HRT story

The long road to causal inference (the “big picture”)



RR_{causal}
“truth”




the long road to causal inference...

$RR_{\text{association}}$



A Skeptic's Algorithm for Associations





TERRY O'DONNELL

"The sin comes in believing a causal hypothesis is true because your study came up with a positive result."

—Sander Greenland

"there is nothing sinful about going out and getting evidence, like asking people how much do you drink and checking breast cancer records. There's nothing sinful about seeing if that evidence correlates. There's nothing sinful about checking for confounding variables. The sin comes in believing a causal hypothesis is true because your study came up with a positive result, or believing the opposite because your study was negative."


Readings for next class

- Article:
 - Taubes G. Epidemiology faces its limits. *Science* 1995
 - Taubes G. Unhealthy Science. NY Times Magazine, 2007
 - Freedman D. Lies, damned lies and medical science. Atlantic, 2010.
- Rothman text:
 - Chapter 1: Intro to epidemiologic thinking
- Gordis text:
 - Chapter 1: Introduction



Your Life

A relational diagram



WWW.PHDCOMICS.COM

JORGE CHAM © 2008